Zusammenfassung
Zu den das Immunsystem beeinflussenden Stoffen gehören solche, die Reaktionen des Immunsystems hemmen (Immunsuppressiva), und solche, die seine Aktivitäten steigern (Immunstimulantien). Hinzu kommen körpereigene Mediatoren des Immunsystems (Interferone, Interleukine, koloniestimulierende Faktoren etc.), die durch die Erfolge der Gentechnologie in größeren Mengen für therapeutische Zwecke hergestellt werden.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
American Cancer Society (2002): Complementary and Alternative Cancer Methods Handbook. American Cancer Society.
Arzneimittelkommission der deutschen Ärzteschaft (1996): Wie verträglich sind Echinacea-haltige Präparate? Dtsch. Ärztebl. 93: A–2723.
Beverly P. (1995): Tumorimmunologie. In: Roitl J.M., Broxtoff J., Male D.K. (Hrsg.): Kurzes Lehrbuch der Immunologie. 3. Aufl. Thieme, Stuttgart New York, S. 246–257.
Brinkeborn R.M., Shah D.V., Degenring RH. (1999): Echinaforce® and other Echinacea fresh plant preparations in the treatment of the common cold. Phytomedicine 6: 1–5.
Collet J.P., Shapiro S., Ernst P., Renzi P., Ducruet T., Robinson A., PARI-IS Study Steering Committee and Research Group (1997): Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Amer. J. Respir. Crit. Care Med. 156: 1719–1724.
Dold U, Edler L., Maeurer H.C. et al. (1991): Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Thieme, Stuttgarts. 1–12.
Dorsch W. (1996): Klinische Anwendung von Extrakten aus Echinacea purpurea oder Echinacea pallida. Klinische Wertung kontrollierter klinischer Studien. Z. Ärztl. Fortbild. (Jena) 90: 117–122.
Dunn C.J., Goa K.L. (2000): Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 59: 681–717.
Ernst E. (2001a): A primer of complementary and alternative medicine commonly used by cancer patients. Med. J. Aust. 174: 88–92.
Ernst E. (2001b): Mistletoe for cancer? Eur. J. Cancer 37: 9–11.
Ernst E. (2001 c): The desktop guide to complementary and alternative medicine an evidence-based approach. Mosby, Hartcourt.
Grimm W., Müller H.-H. (1999): A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am. J. Med. 106: 138–143.
Hajto T., Hostanska K., Frei K., Rordorf C, Gabius H.J. (1990): Increased secretion of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 by human mononuclear cells exposed to b-galactoside-specific lectin from clinically applied mistletoe extracts. Cancer Res. 50: 3322–3326.
Heiny B.M., Albrecht V., Beuth J. (1998): Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactosespecific lectin standardized mistletoe extract. Anticancer Res. 18: 583–586.
Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M. et al. (1996): Intramuscular interferon β-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Colloborative Research Group (MSCRG). Ann. Neurol. 39: 285–294.
Jensen D.M., Krawitt E.L., Keeffe E. B., Hollinger F. B., James S.P., Mullen K. et al. for the Consensus Interferon Study Group (1999): Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Am. J. Gastroenterol. 94: 3583–3588.
Kao J.H., Chen P.J., Lai M.Y., Chen D.S. (2000): Efficacy of consensus interferon in the treatment of chronic hepatitis C. J. Gastroenterol. Hepatol. 15:1418–1423.
Kleijnen J., Knipschild P. (1994): Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1: 255–260.
Lenartz D., Dott U, Menzel J., Schierholz J.M., Beuth J. (2000): Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res. 20: 2073–2076.
McHutchinson J.G., Gordon S.C., Schiff E.R. (1998): Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339: 1485–1492.
Melchart D., Walther E., Linde K., Brandmaier R., Lersch C. (1998): Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch. Farn. Med. 7: 541–545.
Mullins RJ. (1998): Echinacea-associated anaphylaxis. Med. J. Aust. 16: 170–171.
Pforte A., Emmerich B. (1993): Störungen der Infektabwehr bei Patienten mit chronischer Bronchitis: präventive und supportive Möglichkeiten. Pneumologie 47: 395–402.
Scheer R., Bauer R., Becker H., Berg P.A, Fintelmann V. (2001): Vorwort S. V. In: Scheer R. et al. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik, KVC, Essen.
Stein G., Henn W., von Laue H., Berg P. (1998): Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur. J. Med. Res. 3: 194–202.
Steuer-Vogt M.K., Bonkowsky V, Ambrosch P., Scholz M., Neiß A., Strutz J., Hennig M., Lenarz T., Arnold W. (2001): The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur. J. Cancer 37: 23–31.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Zeller, W.J. (2004). Immuntherapeutika und Zytostatika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_30
Download citation
DOI: https://doi.org/10.1007/978-3-642-18512-0_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40188-9
Online ISBN: 978-3-642-18512-0
eBook Packages: Springer Book Archive